Marina Galdino da Rocha Pitta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marina Galdino da Rocha Pitta has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Ivan da Rocha Pitta
Laboratory of Design and Drug Synthesis (LPSF), Nucleus of Research in Therapeutical Innovation Suely Galdino (NUPIT SG), Biosciences Center, Federal University of Pernambuco, Recife, Brazil
6 shared publications - Douglas Carvalho Francisco Viana
Laboratory of Drug Design and Synthesis (LPSF), Nucleus of Research in Therapeutic Innovation (NUPIT‐SG), Center of Biosciences Federal University of Pernambuco Recife Brazil
3 shared publications - Jordy Silva de Carvalho
Universidade Católica de Pernambuco
3 shared publications - José Arion da Silva Moura
Laboratory of Drug Design and Synthesis (LPSF), Nucleus of Research in Therapeutic Innovation (NUPIT‐SG), Center of Biosciences Federal University of Pernambuco Recife Brazil
3 shared publications - Michelly Cristiny Pereira
Universidade Federal de Pernambuco
3 shared publications - Moacyr Jesus Barreto de Melo Rêgo
Universidade Federal de Pernambuco
3 shared publications
Latest Publications
- 3 December 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 78 (1) , 292-302
Thiazolidine derivative (LPSF/CR-35) modulates the production of IL-17A, IL-10, IL-4, TFN, CCL2 and CXCL8 in PBMC from systemic sclerosis patients
Background Systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy, fibrosis, and dysregulation of the immune system. The therapeutic options available for SSc have limited efficacy, and there is a clear need for new pharmacological alternatives. Thiazolidinediones (TZD) are molecules that have therapeutic potential for SSc due to their pharmacological properties. In this study, we aimed to evaluate the immunomodulatory activity of a new TZD analogue (LPSF/CR-35) in peripheral blood mononuclear cells (PBMC) from SSc patients. Materials and methods PBMC response to LPSF/CR-35 (100µM) was examined from SSc patients (n = 19) and healthy control subjects (n = 8) following PBMC stimulation with anti-CD3/CD28. Cytokines (IFN-γ, TNF, IL-2, IL-4, IL-6, IL-10, and IL-17 A) and chemokines (CXCL8/IL-8, CCL5/RANTES, CXCL9/MIG, CCL2/MCP-1, and CXCL10/IP-10) levels were quantified in PBMC culture supernatants by cytometric bead array (CBA). In silico analyses were performed to evaluate the binding affinity of LPSF/CR-35 to peroxisome proliferator-activated receptor gamma (PPARγ). Results LPSF/CR-35 treatment significantly reduced the secretion of IL-17 A (p = 0.02), IL-10 (p = 0.001), IL-4 (p = 0.04), CCL2/MCP-1 (p = 0.003), and CXCL8/IL-8 (p = 0.03), while increasing TNF levels (p = 0.004) in PBMCs from SSc patients. Molecular docking predicted high binding affinity of both E (-9.987 kcal/mol) and Z (-9.992 kcal/mol) isomers of LPSF/CR-35 to PPARγ, supporting a possible PPARγ-dependent mechanism. Conclusions Our results indicate that LPSF/CR-35 modulates key cytokines and chemokines involved in SSc immunopathology, possibly through PPARγ activation. These findings support the potential of LPSF/CR-35 as an immunomodulatory agent in SSc. Further studies are needed to elucidate its effects on fibrosis and confirm its mechanism of action.
- 3 December 2025
- Published by Springer Nature in Pharmacological Reports
- Vol. 78 (1) , 292-302
Thiazolidine derivative (LPSF/CR-35) modulates the production of IL-17A, IL-10, IL-4, TFN, CCL2 and CXCL8 in PBMC from systemic sclerosis patients
Background Systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy, fibrosis, and dysregulation of the immune system. The therapeutic options available for SSc have limited efficacy, and there is a clear need for new pharmacological alternatives. Thiazolidinediones (TZD) are molecules that have therapeutic potential for SSc due to their pharmacological properties. In this study, we aimed to evaluate the immunomodulatory activity of a new TZD analogue (LPSF/CR-35) in peripheral blood mononuclear cells (PBMC) from SSc patients. Materials and methods PBMC response to LPSF/CR-35 (100µM) was examined from SSc patients (n = 19) and healthy control subjects (n = 8) following PBMC stimulation with anti-CD3/CD28. Cytokines (IFN-γ, TNF, IL-2, IL-4, IL-6, IL-10, and IL-17 A) and chemokines (CXCL8/IL-8, CCL5/RANTES, CXCL9/MIG, CCL2/MCP-1, and CXCL10/IP-10) levels were quantified in PBMC culture supernatants by cytometric bead array (CBA). In silico analyses were performed to evaluate the binding affinity of LPSF/CR-35 to peroxisome proliferator-activated receptor gamma (PPARγ). Results LPSF/CR-35 treatment significantly reduced the secretion of IL-17 A (p = 0.02), IL-10 (p = 0.001), IL-4 (p = 0.04), CCL2/MCP-1 (p = 0.003), and CXCL8/IL-8 (p = 0.03), while increasing TNF levels (p = 0.004) in PBMCs from SSc patients. Molecular docking predicted high binding affinity of both E (-9.987 kcal/mol) and Z (-9.992 kcal/mol) isomers of LPSF/CR-35 to PPARγ, supporting a possible PPARγ-dependent mechanism. Conclusions Our results indicate that LPSF/CR-35 modulates key cytokines and chemokines involved in SSc immunopathology, possibly through PPARγ activation. These findings support the potential of LPSF/CR-35 as an immunomodulatory agent in SSc. Further studies are needed to elucidate its effects on fibrosis and confirm its mechanism of action.
- Open Access
- 22 August 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (9) , 1967
Novel Thiazolidinedione Derivatives as Potential ZIKV Antiviral Inhibitors
Zika virus (ZIKV) remains a pressing global health concern due to its association with congenital Zika syndrome and the current lack of approved antiviral therapies. In this study, we evaluated the antiviral activity of three novel thiazolidinedione derivatives, GQ-402, GQ-396, and ZKC-10, against ZIKV in vitro and investigated their potential molecular targets through in silico analysis. GQ-402 exhibited the highest antiviral potency, with an IC50 of 15.7 µM, while ZKC-10 achieved the most substantial reduction in viral RNA levels, as determined by RT-qPCR. Molecular docking studies identified GQ-396 as the top-ranked inhibitor of the NS2B-NS3 protease and NS5 RNA-dependent RNA polymerase, suggesting distinct mechanisms of action among the compounds. These findings highlight the therapeutic potential of thiazolidinedione derivatives and underscore the need for further investigation to develop effective treatments for ZIKV infection.
- 22 August 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (9) , 1967
Open AccessNovel Thiazolidinedione Derivatives as Potential ZIKV Antiviral Inhibitors
Zika virus (ZIKV) remains a pressing global health concern due to its association with congenital Zika syndrome and the current lack of approved antiviral therapies. In this study, we evaluated the antiviral activity of three novel thiazolidinedione derivatives, GQ-402, GQ-396, and ZKC-10, against ZIKV in vitro and investigated their potential molecular targets through in silico analysis. GQ-402 exhibited the highest antiviral potency, with an IC50 of 15.7 µM, while ZKC-10 achieved the most substantial reduction in viral RNA levels, as determined by RT-qPCR. Molecular docking studies identified GQ-396 as the top-ranked inhibitor of the NS2B-NS3 protease and NS5 RNA-dependent RNA polymerase, suggesting distinct mechanisms of action among the compounds. These findings highlight the therapeutic potential of thiazolidinedione derivatives and underscore the need for further investigation to develop effective treatments for ZIKV infection.
- Open Access
- 1 August 2024
- Published by Brazilian Journals in Caderno Pedagógico
- Vol. 21 (8) , e6968
Effects of Ginkgo Biloba on memory and cognitive function in patients with Alzheimer's disease
This integrative review aims to synthesize scientific evidence on the effects of Ginkgo biloba on memory and cognitive function in patients with Alzheimer’s disease. Twenty-five studies published between 2010 and 2023 were analyzed, including randomized clinical trials, observational studies, and systematic reviews. The databases used included PubMed, Scopus, ScienceDirect, and SciELO, with keywords such as "Ginkgo biloba," "Alzheimer's disease," "cognitive function," and "neuroprotection." The results indicate that Ginkgo biloba possesses neuroprotective, antioxidant, and anti-inflammatory properties that contribute to the improvement of cognitive function in patients with Alzheimer's disease. Several studies demonstrated that Ginkgo biloba supplementation results in significant improvements in memory, attention, and executive function. Additionally, the combination of Ginkgo biloba with conventional treatments, such as cholinesterase inhibitors, proved to be particularly effective, enhancing therapeutic effects and offering a more holistic approach to disease management. Despite the promising results, the review highlights the need for more well-controlled, long-term clinical trials to standardize dosages and treatment protocols, as well as to confirm the safety and efficacy of Ginkgo biloba. The variability in study methods and administered dosages was a significant limitation, pointing to the need for further research in this area. In conclusion, Ginkgo biloba emerges as a valuable and promising therapeutic alternative in the management of Alzheimer's disease, offering improvements in cognitive function and quality of life for patients.
- 1 August 2024
- Published by Brazilian Journals in Caderno Pedagógico
- Vol. 21 (8) , e6968
Open AccessEffects of Ginkgo Biloba on memory and cognitive function in patients with Alzheimer's disease
This integrative review aims to synthesize scientific evidence on the effects of Ginkgo biloba on memory and cognitive function in patients with Alzheimer’s disease. Twenty-five studies published between 2010 and 2023 were analyzed, including randomized clinical trials, observational studies, and systematic reviews. The databases used included PubMed, Scopus, ScienceDirect, and SciELO, with keywords such as "Ginkgo biloba," "Alzheimer's disease," "cognitive function," and "neuroprotection." The results indicate that Ginkgo biloba possesses neuroprotective, antioxidant, and anti-inflammatory properties that contribute to the improvement of cognitive function in patients with Alzheimer's disease. Several studies demonstrated that Ginkgo biloba supplementation results in significant improvements in memory, attention, and executive function. Additionally, the combination of Ginkgo biloba with conventional treatments, such as cholinesterase inhibitors, proved to be particularly effective, enhancing therapeutic effects and offering a more holistic approach to disease management. Despite the promising results, the review highlights the need for more well-controlled, long-term clinical trials to standardize dosages and treatment protocols, as well as to confirm the safety and efficacy of Ginkgo biloba. The variability in study methods and administered dosages was a significant limitation, pointing to the need for further research in this area. In conclusion, Ginkgo biloba emerges as a valuable and promising therapeutic alternative in the management of Alzheimer's disease, offering improvements in cognitive function and quality of life for patients.
- 1 December 2023
- Published by Bentham Science Publishers Ltd. in Drug Delivery Letters
- Vol. 13 (4) , 322-328
Genotoxic and Mutagenic Assessment of PT-31, a Molecule with Antipsychotic Potential
The PT-31 molecule, a potential antipsychotic, has demonstrated promising results when orally administrated to in vivo models. A recent study suggested the genotoxic and mutagenic potential of PT-31 after acute treatment by intraperitoneal route. This study aimed to evaluate PT-31 potential of inducing genotoxic or mutagenic damage after acute oral administration. For that, adult males and females Balb/C mice were treated acutely by oral administration with vehicle or PT-31 in three different doses (10, 20, and 40 mg kg-1). After 24 hours from PT-31 administration, animals were euthanized for performing the comet and micronucleus assays. None of the tested groups of PT-31 presented a significant increase in damage index and MN frequency. However, they presented the following tendency on damage index: females presented a tendency at 40 mg kg-1 and males at 20 mg kg-1. Regarding the MN assay, male mice at the highest dose of 40 mg kg-1 presented a tendency of increased MN frequency. Also, there was a significant increase in PCE/NCE ratio in male mice. Results suggest that the male mice group presented higher susceptibility to damage. The tendency of increased damage to DNA and MN frequency suggests that the molecule PT-31 may induce reparable damage to DNA, and these DNA strand repairs may have originated from the MN. However, significant genotoxic and mutagenic effects were not observed. This study reinforces the atypicality of the molecule as much as its safety by oral route administration.
- 1 December 2023
- Published by Bentham Science Publishers Ltd. in Drug Delivery Letters
- Vol. 13 (4) , 322-328
Genotoxic and Mutagenic Assessment of PT-31, a Molecule with Antipsychotic Potential
The PT-31 molecule, a potential antipsychotic, has demonstrated promising results when orally administrated to in vivo models. A recent study suggested the genotoxic and mutagenic potential of PT-31 after acute treatment by intraperitoneal route. This study aimed to evaluate PT-31 potential of inducing genotoxic or mutagenic damage after acute oral administration. For that, adult males and females Balb/C mice were treated acutely by oral administration with vehicle or PT-31 in three different doses (10, 20, and 40 mg kg-1). After 24 hours from PT-31 administration, animals were euthanized for performing the comet and micronucleus assays. None of the tested groups of PT-31 presented a significant increase in damage index and MN frequency. However, they presented the following tendency on damage index: females presented a tendency at 40 mg kg-1 and males at 20 mg kg-1. Regarding the MN assay, male mice at the highest dose of 40 mg kg-1 presented a tendency of increased MN frequency. Also, there was a significant increase in PCE/NCE ratio in male mice. Results suggest that the male mice group presented higher susceptibility to damage. The tendency of increased damage to DNA and MN frequency suggests that the molecule PT-31 may induce reparable damage to DNA, and these DNA strand repairs may have originated from the MN. However, significant genotoxic and mutagenic effects were not observed. This study reinforces the atypicality of the molecule as much as its safety by oral route administration.
- 1 April 2022
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 23 (5) , 441-457
New Trends in Biological Activities and Clinical Studies of Quinolinic Analogues: A Review
: The quinolinic ring, present in several molecules, possesses a great diversity of biological activities. Therefore, this ring is in the structural composition of several candidates of drugs in pre-clinical and clinical studies; thus, it is necessary to compile these results to facilitate the design of new drugs. For this reason, some of the activities of compounds are selected to examine in this re-view, such as antimalarial, antimicrobial, anticancer, anti-inflammatory, antidiabetic, anti-rheumatic, and antiviral activities. All publications of scientific articles chosen are dated between 2000 and 2020. In addition to presenting the structures of some natural and synthetic compounds with their activities, we have listed the clinical studies of phases III and IV on antimalarial drugs containing the quinoline nucleus and phase III clinical studies on hydroxychloroquine and chloroquine to assess their possible role in COVID-19. Finally, we have reviewed some of the mechanisms of action, as well as the side effects of some of the quinolinic derivatives.
- 1 April 2022
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 23 (5) , 441-457
New Trends in Biological Activities and Clinical Studies of Quinolinic Analogues: A Review
: The quinolinic ring, present in several molecules, possesses a great diversity of biological activities. Therefore, this ring is in the structural composition of several candidates of drugs in pre-clinical and clinical studies; thus, it is necessary to compile these results to facilitate the design of new drugs. For this reason, some of the activities of compounds are selected to examine in this re-view, such as antimalarial, antimicrobial, anticancer, anti-inflammatory, antidiabetic, anti-rheumatic, and antiviral activities. All publications of scientific articles chosen are dated between 2000 and 2020. In addition to presenting the structures of some natural and synthetic compounds with their activities, we have listed the clinical studies of phases III and IV on antimalarial drugs containing the quinoline nucleus and phase III clinical studies on hydroxychloroquine and chloroquine to assess their possible role in COVID-19. Finally, we have reviewed some of the mechanisms of action, as well as the side effects of some of the quinolinic derivatives.
- 1 February 2022
- Published by Elsevier in Bioorganic Chemistry
- Vol. 119, 105548
Synthesis of novel thiazolidinic-phthalimide derivatives evaluated as new multi-target antiepileptic agents
- 1 February 2022
- Published by Elsevier in Bioorganic Chemistry
- Vol. 119, 105548
Synthesis of novel thiazolidinic-phthalimide derivatives evaluated as new multi-target antiepileptic agents
- 17 November 2021
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 31 (1) , 108-119
Synthesis and biological activities of new phthalimide and thiazolidine derivatives
- 17 November 2021
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 31 (1) , 108-119
Synthesis and biological activities of new phthalimide and thiazolidine derivatives
- Open Access
- 31 August 2021
- Published by Springer Nature in Research Square
Design, Synthesis and Biological Activities of New Phthalimide and Thiazolidine Derivatives
The combination of pharmacophoric nuclei with different targets has been a strategy for the development of new drugs aimed at improving cancer treatment. A series of ten novel phthalimido-thiazolidine-2-4-dione derivatives were synthesized by two different synthetic routes. The compounds were tested and evaluated in vitro, through antineoplastic activities against cancer cells. Cell cycle analyzes and clonogenic assay were also performed. In addition to these tests, in silico predictions were performed. The synthesized FT-12 compound (9j) exhibited antiproliferative activity against Panc-1, Sk-mel-28 and PC-3 cells. FT-12 reduced the ability to form new clones, also caused irreversibility in cell cycle, inducing arrest in phase S. Besides, the compound (FT-12) caused necrosis and apoptosis. The results suggest that phthalimido-thiazolidine derivatives may be useful in cancer therapy, highlighting compound FT-12 (9j) as a promising candidate. More studies must be carried out to confirm the viability.
- 31 August 2021
- Published by Springer Nature in Research Square
Open AccessDesign, Synthesis and Biological Activities of New Phthalimide and Thiazolidine Derivatives
The combination of pharmacophoric nuclei with different targets has been a strategy for the development of new drugs aimed at improving cancer treatment. A series of ten novel phthalimido-thiazolidine-2-4-dione derivatives were synthesized by two different synthetic routes. The compounds were tested and evaluated in vitro, through antineoplastic activities against cancer cells. Cell cycle analyzes and clonogenic assay were also performed. In addition to these tests, in silico predictions were performed. The synthesized FT-12 compound (9j) exhibited antiproliferative activity against Panc-1, Sk-mel-28 and PC-3 cells. FT-12 reduced the ability to form new clones, also caused irreversibility in cell cycle, inducing arrest in phase S. Besides, the compound (FT-12) caused necrosis and apoptosis. The results suggest that phthalimido-thiazolidine derivatives may be useful in cancer therapy, highlighting compound FT-12 (9j) as a promising candidate. More studies must be carried out to confirm the viability.
- Open Access
- 21 August 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (11)
Análise do perfil de automedicação em tempos de COVID-19 no Brasil
Este manuscrito buscou a identificação do perfil brasileiro de automedicação na pandemia de COVID-19 e a reunião de informações sociodemográficas relacionadas ao uso da automedicação. Para tanto, foi investigado o conceito que os participantes depreendem sobre a automedicação, além de examinar qual o tipo de medicamento utilizado por quem se automedicou e seus efeitos colaterais. Foi realizada uma pesquisa no período de 03 de agosto a 30 de setembro de 2020. Os participantes deveriam apresentar uma idade mínima de 18 anos. As amostras estavam centradas em quem residia no Brasil. A pesquisa incluiu pessoas da população em geral. A coleta de dados se deu através de um questionário online, pois no referido período, as entrevistas presenciais deveriam ser evitadas devido ao contínuo lockdown. Coletaram-se dados de 1000 participantes para esta pesquisa. Os medicamentos que prevaleceram são da classe das vitaminas e, em segundo lugar, a Ivermectina. Destacou-se a indicação de automedicação por familiares. Os maiores índices de efeitos colaterais registrados foram cólicas intestinais e mal-estar. A prática da automedicação no Brasil mostrou-se preocupante no período de pandemia provocado pela COVID-19. Sendo assim, é importante que a população esteja atenta e seja criteriosa acerca das fontes de informações que discorrem sobre os medicamentos, evitando assim decisões precipitadas que podem ser mais prejudiciais.
- 21 August 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (11)
Open AccessAnálise do perfil de automedicação em tempos de COVID-19 no Brasil
Este manuscrito buscou a identificação do perfil brasileiro de automedicação na pandemia de COVID-19 e a reunião de informações sociodemográficas relacionadas ao uso da automedicação. Para tanto, foi investigado o conceito que os participantes depreendem sobre a automedicação, além de examinar qual o tipo de medicamento utilizado por quem se automedicou e seus efeitos colaterais. Foi realizada uma pesquisa no período de 03 de agosto a 30 de setembro de 2020. Os participantes deveriam apresentar uma idade mínima de 18 anos. As amostras estavam centradas em quem residia no Brasil. A pesquisa incluiu pessoas da população em geral. A coleta de dados se deu através de um questionário online, pois no referido período, as entrevistas presenciais deveriam ser evitadas devido ao contínuo lockdown. Coletaram-se dados de 1000 participantes para esta pesquisa. Os medicamentos que prevaleceram são da classe das vitaminas e, em segundo lugar, a Ivermectina. Destacou-se a indicação de automedicação por familiares. Os maiores índices de efeitos colaterais registrados foram cólicas intestinais e mal-estar. A prática da automedicação no Brasil mostrou-se preocupante no período de pandemia provocado pela COVID-19. Sendo assim, é importante que a população esteja atenta e seja criteriosa acerca das fontes de informações que discorrem sobre os medicamentos, evitando assim decisões precipitadas que podem ser mais prejudiciais.
- Open Access
- 3 August 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (10)
Nanocarreadores aplicados ao tratamento do câncer de mama
Objetivo: Avaliar as implicações da utilização dos nanocarreadores no tratamento do câncer de mama. Métodos: Revisão da literatura com base nas diretrizes contidas no Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA), utilizando as bases de dados: PubMed e Biblioteca Virtual em Saúde com os termos de busca: “nanopartículas” E “tratamento” E “câncer de mama”. Foram selecionados 19 artigos, escritos em inglês, que preencheram os critérios de inclusão. Resultados: Diante dos achados nos estudos selecionados, percebeu-se que os nanocarreadores apresentam baixa toxicidade a células saudáveis e as nanopartículas podem ser direcionadas para o local específico do tumor. Conclusão: este estudo permitiu compreender a eficácia das drogas utilizadas nos diferentes tipos de nanocarreadores para a redução das células tumorais com minimização da toxicidade e liberação do medicamento na região específica do tumor.
- 3 August 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (10)
Open AccessNanocarreadores aplicados ao tratamento do câncer de mama
Objetivo: Avaliar as implicações da utilização dos nanocarreadores no tratamento do câncer de mama. Métodos: Revisão da literatura com base nas diretrizes contidas no Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA), utilizando as bases de dados: PubMed e Biblioteca Virtual em Saúde com os termos de busca: “nanopartículas” E “tratamento” E “câncer de mama”. Foram selecionados 19 artigos, escritos em inglês, que preencheram os critérios de inclusão. Resultados: Diante dos achados nos estudos selecionados, percebeu-se que os nanocarreadores apresentam baixa toxicidade a células saudáveis e as nanopartículas podem ser direcionadas para o local específico do tumor. Conclusão: este estudo permitiu compreender a eficácia das drogas utilizadas nos diferentes tipos de nanocarreadores para a redução das células tumorais com minimização da toxicidade e liberação do medicamento na região específica do tumor.